No Data
No Data
Is It a Good Idea to Invest in Beam Therapeutics Stock Now?
Bernstein Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $37
Beam Therapeutics to Encore Data From BEACON Phase 1/2 Trial of Beam-101
Beam Therapeutics to Encore Data From BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
Express News | Beam Therapeutics to Encore Data From Beacon Phase 1/2 Clinical Trial of Beam-101 in Sickle Cell Disease at 2025 Tandem Meetings of Astct and Cibmtr
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation